Burkitt's lymphoma cell, is a cancer of the lymphatic system

New Research Findings, Computational Health, ICB, Molecular Targets and Therapeutics, SAT,

Aggressive Blood Cancer: Contribution of Enzyme MALT1 Uncovered

A team of researchers from Helmholtz Munich in cooperation with scientists at the University Hospital Münster (UKM) has uncovered a new pathway that promotes the growth of aggressive blood cancer, so-called lymphomas. Survival of many lymphomas…

Daniel Krappmann Portrait SAT

Molecular Targets and Therapeutics, SAT,

“We aim to deliver new therapeutic concepts on how to intervene with cell signaling networks.”

Daniel Krappmann about his new Research Unit "Signaling and Translation" at Helmholtz Munich

The X-ray of the human brain closeup image

Transfer, Awards & Grants, SAT,

Targeting Brain Tumors: New Drug Candidate in Clinical Trial

Clinical trials are a milestone in the development of safe and effective drugs and therapies. An antibody developed by Helmholtz Munich is now entering a phase 1 clinical trial. Together with the radiopharmaceutical company ITM Isotope Technologies…

Stapel Zeitschriften

SAT,

Group Signaling and Immunity publishes manuscript in Frontier in Immunology on the tight crosstalk of TRAF6 and MALT1 in T cells.

Holding Tablet PC

SAT,

Research Unit Signaling & Translation (SAT) established

www.helmholtz-munich.de/en/sat